Patho.ai

Patho.ai develops generative-AI software and hardware for drug discovery, aiming to connect computational predictions with automated chemical synthesis. Its research portfolio includes Navi Cell, an AI-designed small-molecule inhibitor targeting AP2A1 cellular senescence; Patho Kappa, a targeted protein degrader for neurodegenerative diseases; and Syntho Core, an immune-modulator using graph alignments. These are development projects, with work spanning molecular design and potential treatments.

Founder Chin Keong Lam identified himself as Patho.ai’s CEO in 2018, when he offered consultancy on medical and precision robots using ROS. The company’s more recent technical approach combines a proprietary knowledge-augmented generation framework grounded in physical laws with precision-calibrated automated gantries for chemical synthesis. The intended connection is between AI-generated predictions and equipment that can produce physical chemical assets.

Based in Palo Alto, Patho.ai describes its work as a preclinical proof of concept that it is scaling. Its stated cancer-drug research includes exploring synthesis pathways for lower-cost alternatives to immunotherapy drugs. This places its focus on developing drug-discovery and synthesis capabilities, with affordability an objective rather than an established treatment outcome.